Bristol-Myers Slides After Another Lung Cancer Drug Setback

Shares of Bristol-Myers Squibb are sliding after the company announced that it will not pursue an accelerated regulatory path for the Opdivo/Yervoy combination, with research firm Cowen downgrading the stock to Market Perform following the news.